Brain nutrition starts with what brain cells use. DHA is part of their membranes. Lithium orotate adds a different research story: promising findings on cellular changes and memory in mice. Semaine’s proposed Brain Longevity formula brings 420 mg algae-derived DHA and 1 mg elemental lithium together in one vegetarian capsule. The combination has not been shown to improve memory in people.
Does DHA lower dementia and Alzheimer's risk?
Observational evidence points that way, though it cannot prove cause. In the Framingham Offspring cohort (Sala-Vila and colleagues, 2022, Nutrients; 1,490 dementia-free adults aged 65 and over), the highest versus lowest red-blood-cell DHA group had roughly 49% lower incident Alzheimer's disease (hazard ratio about 0.51; DOI). A large UK Biobank analysis (He and colleagues, 2023, GeroScience; 440,750 participants) found higher plasma DHA associated with lower dementia risk (hazard ratio about 0.92 per standard deviation), with fish-oil users showing roughly 7% lower all-cause dementia (DOI).
What do the numbers say about DHA and dementia?
| Source | Year | Design | Sample | Key finding |
|---|---|---|---|---|
| Sala-Vila and colleagues (Framingham Offspring) | 2022 | Prospective cohort | 1,490 (age 65+) | Highest vs lowest red-blood-cell DHA: about 49% lower incident Alzheimer's |
| He and colleagues (UK Biobank) | 2023 | Prospective cohort | 440,750 | Plasma DHA: dementia HR about 0.92 per SD; fish-oil users about 7% lower all-cause dementia |
| Randomized-trial caveat (multiple) | various | RCTs | , | Generally limited or null efficacy for slowing decline or preventing Alzheimer's |
How does ApoE4 affect the DHA picture?
APOE ε4 is a genetic variant associated with higher Alzheimer’s risk. Researchers are studying whether it also changes DHA delivery to the brain or responses to supplementation. A small 2020 trial examined brain delivery, while a 2023 PreventE4 publication described a larger trial’s baseline findings. Neither publication establishes that APOE ε4 carriers should take a particular DHA dose.
What human trials tell us about DHA and lithium
Trials of cognition and trials of dementia prevention ask different questions. MIDAS reported improved learning after 24 weeks of 900 mg DHA daily in older adults with age-related cognitive concerns. Other trials have reported no cognitive benefit. A positive result at one dose does not establish a benefit at 420 mg, and selected test improvements do not prove dementia prevention. Read the MIDAS trial.
Lithium orotate has not been adequately studied in humans to establish its effects on memory or long-term safety. Human trials of lithium carbonate and other forms do not answer that question for orotate. The promising orotate findings discussed here come from mice. Read the lithium-orotate research review.
Why is DHA discussed alongside lithium?
DHA supplies a structural component of brain-cell membranes. Lithium orotate was selected for findings on lithium availability and memory in mice. That gives the two ingredients distinct roles in the proposed formula’s rationale, with the convenience of one capsule. Human testing is still needed to establish the combination’s effects. Explore the lithium studies.
Limitations and safety
Higher DHA status has been associated with lower dementia risk, but that does not prove a supplement prevents disease. Clinical findings vary by population, dose, and outcome; the 420 mg DHA plus 1 mg elemental lithium from orotate formula remains untested. Review the full ingredient list and precautions for a lithium-containing supplement with your clinician, particularly with medicines, kidney or thyroid conditions, or during pregnancy or breastfeeding.
Frequently asked questions
Does DHA prevent Alzheimer's disease?
DHA has not been established as a way to prevent Alzheimer’s disease. Higher blood DHA has been associated with lower risk, and selected supplement trials have reported memory or learning findings. Those outcomes do not establish disease prevention.
How much does omega-3 reduce dementia risk?
In observational data, a large UK Biobank analysis linked higher plasma DHA to lower dementia risk (hazard ratio about 0.92 per standard deviation). These are associations from cohort studies, not proven causal reductions.
Should ApoE4 carriers take more DHA?
There is no established APOE ε4-specific DHA recommendation in the evidence discussed here. Genetic risk and supplement dosing are best considered with a clinician, rather than inferred from a single cohort or a brain-delivery study.
Why do DHA supplements look good in cohorts but fall short in trials?
Proposed reasons include intervening too late, too low a dose or short duration, reduced brain delivery in some genetic subgroups, and differences between dietary and supplement contexts. These are possible explanations, not proven ways to turn an association into a treatment benefit.
Is it worth combining lithium and DHA?
DHA’s role in brain-cell membranes and lithium orotate’s promising mouse findings are distinct reasons for the proposed combination. Brain Longevity brings the specified ingredients into one capsule. Added memory benefit from combining them has not been established in a human trial.
